@article {Walker:2018:1027-3719:773,
title = "Depression among multidrug-resistant tuberculosis patients in Punjab, Pakistan: a large cross-sectional study",
journal = "The International Journal of Tuberculosis and Lung Disease",
parent_itemid = "infobike://iuatld/ijtld",
publishercode ="iuatld",
year = "2018",
volume = "22",
number = "7",
publication date ="2018-07-01T00:00:00",
pages = "773-778",
itemtype = "ARTICLE",
issn = "1027-3719",
eissn = "1815-7920",
url = "https://www.ingentaconnect.com/content/iuatld/ijtld/2018/00000022/00000007/art00012",
doi = "doi:10.5588/ijtld.17.0788",
keyword = "depression, tuberculosis, epidemiology, drug resistance",
author = "Walker, I. F. and Khan, Ahmar M. and Khan, Amir M. and Khan, N. M. and Ayub, R. M. and Ghias, K. N. and Walley, J. D.",
abstract = "BACKGROUND AND OBJECTIVES: Depression is likely to be a factor in the low global rates of successful treatment for multidrug-resistant tuberculosis (MDR-TB) due to poor adherence to treatment. We aimed to estimate the prevalence of depression among patients being treated for MDR-TB
in Pakistan, explore rates of depression over the course of treatment and identify risk factors for depression.DESIGN: This cross-sectional study analysed health care service data from 12 treatment sites following a single screening event using the Patient Health Questionnaire 9 (PHQ-9).
Logistic regression models were used to identify associations.RESULTS: Data were collected from 1279 patients with MDR-TB. The proportion of MDR-TB patients with depression was 42.8% (95%CI 40.145.5). Rates of depression varied according to duration of treatment, with the highest
proportion (53.2%) found in those who were in months 1012 of treatment. The odds of depression in women were higher than for men (adjusted odds ratio [aOR] 1.84, 95%CI 1.462.33). The odds of depression were higher in patients living in concrete-built houses than in those living
in mud-built houses (aOR 1.37, 95%CI 1.031.82).CONCLUSION: Depression is common in MDR-TB patients, and should be screened for and treated within MDR-TB treatment programmes.",
}